Biology of Blood and Marrow Transplantation
Volume 12, Issue 5 , Pages 552-559 , May 2006

Voriconazole and Sirolimus Coadministration after Allogeneic Hematopoietic Stem Cell Transplantation

  • Francisco M. Marty

      Affiliations

    • Division of Infectious Diseases, Brigham & Women’s Hospital, Boston, Massachusetts, USA
    • Dana-Farber Cancer Institute, Boston, Massachusetts, USA
    • Harvard Medical School, Boston, Massachusetts, USA
    • Corresponding Author InformationCorrespondence and reprint requests: Francisco M. Marty, MD, Division of Infectious Diseases, Brigham & Women’s Hospital, 75 Francis St., PBB-A4, Boston, MA 02115
    • ,
  • Colleen M. Lowry

      Affiliations

    • Department of Pharmacy, Brigham & Women’s Hospital, Boston, Massachusetts, USA
    • ,
  • Corey S. Cutler

      Affiliations

    • Dana-Farber Cancer Institute, Boston, Massachusetts, USA
    • Harvard Medical School, Boston, Massachusetts, USA
    • Division of Medical Oncology, Brigham & Women’s Hospital, Boston, Massachusetts
    • ,
  • Bonnie J. Campbell

      Affiliations

    • Department of Pharmacy, Brigham & Women’s Hospital, Boston, Massachusetts, USA
    • ,
  • Karen Fiumara

      Affiliations

    • Department of Pharmacy, Brigham & Women’s Hospital, Boston, Massachusetts, USA
    • ,
  • Lindsey R. Baden

      Affiliations

    • Division of Infectious Diseases, Brigham & Women’s Hospital, Boston, Massachusetts, USA
    • Dana-Farber Cancer Institute, Boston, Massachusetts, USA
    • Harvard Medical School, Boston, Massachusetts, USA
    • ,
  • Joseph H. Antin

      Affiliations

    • Dana-Farber Cancer Institute, Boston, Massachusetts, USA
    • Harvard Medical School, Boston, Massachusetts, USA
    • Division of Medical Oncology, Brigham & Women’s Hospital, Boston, Massachusetts

Received 4 November 2005 ,Accepted 12 December 2005.

References 

  1. Cutler C , Antin JH . Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation . Bone Marrow Transplant . 2004;34:471–476
  2. MacDonald AS . Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation . Transplant Proc . 2003;35(3 suppl):201S–208S
  3. Antin JH , Kim HT , Cutler C , et al.   Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation . Blood . 2003;102:1601–1605
  4. Cutler C , Kim HT , Hochberg E , et al.   Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation . Biol Blood Marrow Transplant . 2004;10:328–336
  5. Marty FM , Lee SJ , Fahey MM , et al.   Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients (a cohort study) . Blood . 2003;102:2768–2776
  6. Singh N , Paterson DL . Aspergillus infections in transplant recipients . Clin Microbiol Rev . 2005;18:44–69
  7. Marr KA , Carter RA , Crippa F , Wald A , Corey L . Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients . Clin Infect Dis . 2002;34:909–917
  8. Herbrecht R , Denning DW , Patterson TF , et al.   Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis . N Engl J Med . 2002;347:408–415
  9. Center for Drug Evaluation and Research, Food and Drug Administration . NDA 21-266 and 21-267, Vfend™⃝ (voriconazole) . 2002; May 24. Available at: http://www.fda.gov/cder/foi/appletter/2002/21266ltr.pdf. Accessed August 21, 2005
  10. Perfect JR , Marr KA , Walsh TJ , et al.   Voriconazole treatment for less-common, emerging, or refractory fungal infections . Clin Infect Dis . 2003;36:1122–1131
  11. Product Information (Vfend(R), Voriconazole) . New York: Pfizer Inc; 2005;
  12. Abel S , Allan R , Fielding A . Effect of voriconazole on the pharmacokinetics of sirolimus (poster) . 12th European Congress of Clinical Microbiology and Infectious Diseases . 2002; April 24-27, Milan, Italy
  13. Ascioglu S , Rex JH , de Pauw B , et al.   Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants (an international consensus) . Clin Infect Dis . 2002;34:7–14
  14. Ho VT , Cutler C , Carter S , et al.   Blood and marrow transplant clinical trials network toxicity committee consensus summary (thrombotic microangiopathy after hematopoietic stem cell transplantation) . Biol Blood Marrow Transplant . 2005;11:571–575
  15. Cutler C , Henry NL , Magee C , et al.   Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation . Biol Blood Marrow Transplant . 2005;11:551–557
  16. Mathis AS , Shah NK , Friedman GS . Combined use of sirolimus and voriconazole in renal transplantation (a report of two cases) . Transplant Proc . 2004;36:2708–2709
  17. Garrean S , Massad MG , Tshibaka M , Hanhan Z , Caines AE , Benedetti E . Sirolimus-associated interstitial pneumonitis in solid organ transplant recipients . Clin Transplant . 2005;19:698–703
  18. Morelon E , Stern M , Israel-Biet D , et al.   Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients . Transplantation . 2001;72:787–790
  19. Morelon E , Stern M , Kreis H . Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients . N Engl J Med . 2000;343:225–226
  20. Singer SJ , Tiernan R , Sullivan EJ . Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients . N Engl J Med . 2000;343:1815–1816
  21. Vlahakis NE , Rickman OB , Morgenthaler T . Sirolimus-associated diffuse alveolar hemorrhage . Mayo Clin Proc . 2004;79:541–545
  22. Tintillier M , Kirch L , Goffin E , Cuvelier C , Pochet JM . Interaction between voriconazole and tacrolimus in a kidney-transplanted patient . Nephrol Dial Transplant . 2005;20:664–665
  23. Venkataramanan R , Zang S , Gayowski T , Singh N . Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes . Antimicrob Agents Chemother . 2002;46:3091–3093
  24. Piscitelli SC , Rodvold K . Drug Interactions in Infectious Diseases . 2nd ed.. Totowa, NJ: Humana Press; 2005;
  25. Yasuda K , Lan LB , Sanglard D , Furuya K , Schuetz JD , Schuetz EG . Interaction of cytochrome P450 3A inhibitors with P-glycoprotein . J Pharmacol Exp Ther . 2002;303:323–332
  26. Paine MF , Leung LY , Lim HK , et al.   Identification of a novel route of extraction of sirolimus in human small intestine (roles of metabolism and secretion) . J Pharmacol Exp Ther . 2002;301:174–186

PII: S1083-8791(05)01414-X

doi: 10.1016/j.bbmt.2005.12.032

Biology of Blood and Marrow Transplantation
Volume 12, Issue 5 , Pages 552-559 , May 2006

Article Tools